Innovations in Inflammatory Bowel Disease Therapy: How IL-23 Inhibitors Are Shaping Treatment and Managed Care Approaches
May 20, 2025 | 1:00 PM and 8:00 PM ET
View More
Navigating Next-Generation Therapies for the Management of Acid-Related Disorders
1.5 Credits / Gastroenterology
View More
Managed Care Insights on the Advances in the Eosinophilic Esophagitis Treatment Landscape
1.0 Credit / Gastroenterology, Immunology, Rare Diseases
View More
MA Beneficiaries May Be at Disadvantage for Complex Cancer Surgeries
November 21st 2022Patients with Medicare Advantage (MA) were 1.5 times more likely to die within a month of surgical removal of their stomach or liver, and twice as likely to die within a month of oncologic surgery of the pancreas, compared with patients with traditional Medicare.
Read More
Change in Smoking Status and Subsequent BMI Change Linked to NAFLD Risk
November 3rd 2022Across 4 types of smoking status groups, nonalcoholic fatty liver disease (NAFLD) risk significantly increased among participants who saw an increase in body mass index (BMI) and decreased among participants whose BMI went down.
Read More
New ICD-10 Code Aims to Provide More Insight Into Hepatic Encephalopathy
October 26th 2022In an interview, the section chief of hepatology at Rush University Medical Center discussed why the addition of the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis code K76.82 is necessary.
Read More
Albumin Injections Linked to Improved Brain Function, QOL in Patients With Liver Cirrhosis
October 21st 2022Researchers also found an improvement in specialized blood markers focusing on inflammation, endothelial dysfunction, and albumin function in patients receiving weekly albumin injection.
Read More
ICER to Assess Clinical Effectiveness, Value of 2 NASH Treatments
October 11th 2022There are no FDA-approved therapies for nonalcoholic steatohepatitis (NASH), but there are many being developed. Resmetirom and obeticholic acid are both being reviewed by the FDA with decisions expected in 2023.
Read More
Higher Risk of Liver Disease Progression Seen Among Patients With PNPLA3 I148M Variant
October 7th 2022Individuals who were homozygous carriers of the PNPLA3 I148M genetic variant and reported excessive drinking and obesity had a 17.5 to 30.1 higher risk of progression to liver disease complications.
Read More
Dr Pichamol Jirapinyo Discusses Endoscopic Gastric Plication in Patients With NAFLD
September 22nd 2022Pichamol Jirapinyo, MD, MPH, director of bariatric endoscopy fellowship at Brigham and Women's Hospital, explains the implications of her study on the effects of endoscopic gastric plication on liver fibrosis in patients with nonalcoholic steatohepatitis (NASH).
Read More
Optimizing Emergency Care Processes Improves Outcomes for Hospitalized Patients With HE
September 16th 2022Patients with hepatic encephalopathy (HE) often do not seek care until they are in critical condition, making an optimized emergency care process critical to reduce adverse prognosis and improve clinical symptoms.
Read More
Rifaximin Plus Lactulose Linked to Greater Effectiveness, Decreased Mortality in HE
September 9th 2022Compared with the use of lactulose alone, rifaximin plus lactulose can provide additional benefits in terms of increased effectiveness rate and decreased mortality in patients with hepatic encephalopathy (HE).
Read More
Study Finds First-Degree Family History of Diabetes Linked With NAFLD
December 19th 2021Using the fatty liver index (FLI) to identify nonalcoholic fatty liver disease (NAFLD), researchers sought to understand the association between first-degree family members of patients with diabetes and NAFLD.
Read More
Educational Interventions Are Needed to Address Knowledge Gaps for Management of NASH
December 13th 2021Two posters presented at The Liver Meeting identified the primary care coordinators for patients with nonalcoholic steatohepatitis (NASH) and areas of unmet need among specialists to provide optimal management.
Read More